Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: A meta-analysis

European Urology

Volumn 65, Issue 2, 2014, Pages 350-357

  Petrelli, Fausto ^a   Coinu, Andrea ^a   Cabiddu, Mary ^a   Ghilardi, Mara ^a   Vavassori, Ivano ^a   Barni, Sandro ^a  

^a TREVIGLIO HOSPITAL   (Italy)

Author keywords

Bladder cancer; Neoadjuvant chemotherapy; Overall survival; pCR; Prognostic factor

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; PLATINUM; VINBLASTINE;

ATTRIBUTABLE RISK; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RISK; CANCER SPECIFIC SURVIVAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL (TOPIC); CORRELATION ANALYSIS; CYSTECTOMY; DISTANT RECURRENCE FREE SURVIVAL; HUMAN; LOCAL RECURRENCE FREE SURVIVAL; META ANALYSIS; MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; PRIMARY TUMOR; PRIORITY JOURNAL; PUBLICATION; PUBLISHING; RECURRENCE FREE SURVIVAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

BLADDER CANCER; NEOADJUVANT CHEMOTHERAPY; OVERALL SURVIVAL; PCR; PROGNOSTIC FACTOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; CYSTECTOMY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ODDS RATIO; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84891830511     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.06.049     Document Type: Review

References (37)

1. C.N. Sternberg, A. Yagoda, and H.I. Scher et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium J Urol 133 1985 403 407
2. H. von der Maase, S.W. Hansen, and J.T. Roberts et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 18 2000 3068 3077
3. Advanced Bladder Cancer Meta-analysis Collaboration Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis Lancet 361 2003 1927 1934
4. H.B. Grossman, R.B. Natale, and C.M. Tangen et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer [published correction appears in N Engl J Med 2003;349:1880] N Engl J Med 349 2003 859 866
5. T. Granfors, R. Tomic, and B. Ljungberg Downstaging and survival benefits of neoadjuvant radiotherapy before cystectomy for patients with invasive bladder carcinoma Scand J Urol Nephrol 43 2009 293 299
6. M.E. Nielsen, P.J. Bastian, and G.S. Palapattu et al. Recurrence-free survival after radical cystectomy of patients downstaged by transurethral resection Urology 70 2007 1091 1095
7. J.A. Martinez-Piñeiro, M. Gonzalez Martin, and F. Arocena et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study J Urol 153 1995 964 973
8. A. Dash, J.A. Pettus IV, and H.W. Herr et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience Cancer 113 2008 2471 2477
9. G. Sonpavde, B.H. Goldman, and V.O. Speights et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy Cancer 115 2009 4104 4109
10. R. Rosenblatt, A. Sherif, and E. Rintala et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer Eur Urol 61 2012 1229 1238
11. R.P. Meijer, J.A. Nieuwenhuijzen, and W. Meinhardt et al. Response to induction chemotherapy and surgery in non-organ confined bladder cancer: a single institution experience Eur J Surg Oncol 39 2013 365 371
12. G. Kaneko, E. Kikuchi, and K. Matsumoto et al. Neoadjuvant gemcitabine plus cisplatin for muscle-invasive bladder cancer Jpn J Clin Oncol 41 2011 908 914
13. P. Ghadjar, F.C. Burkhard, O. Gautschi, G.N. Thalmann, and U.E. Studer Induction chemotherapy for unresectable urothelial carcinoma of the bladder BJU Int 107 2011 894 897
14. Y. Matsui, H. Nishiyama, and J. Watanabe et al. The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan Int J Clin Oncol 10 2005 133 138
15. C.N. Sternberg, V. Pansadoro, and F. Calabro et al. Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder Ann Oncol 10 1999 1301 1305
16. V. Scattoni, A. Bolognesi, and C. Cozzarini et al. Neoadjuvant CMV chemotherapy plus radical cystectomy in locally advanced bladder cancer: the impact of pathologic response on long-term results Tumori 82 1996 463 469
17. S.M. Donat, H.W. Herr, and D.F. Bajorin et al. Methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and cystectomy for unresectable bladder cancer J Urol 156 1996 368 371
18. P. Sagaster, J. Flamm, and M. Flamm et al. Neoadjuvant chemotherapy (MVAC) in locally invasive bladder cancer Eur J Cancer 32A 1996 1320 1324
19. H.W. Herr, and H.I. Scher Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer J Clin Oncol 12 1994 975 980
20. P.A. Hatcher, R.G. Hahn, R.L. Richardson, and H. Zincke Neoadjuvant chemotherapy for invasive bladder carcinoma: disease outcome and bladder preservation and relationship to local tumor response Eur Urol 25 1994 209 215
21. R. Dreicer, T.A. Kollmorgen, R.F. Smith, and R.D. Williams Neoadjuvant cisplatin, methotrexate and vinblastine for muscle-invasive bladder cancer: long-term followup J Urol 150 1993 849 852
22. P.E. Clark, N. Agarwal, and M.C. Biagioli et al. Bladder cancer J Natl Compr Canc Netw 11 2013 446 475
23. C.N. Sternberg, J. Bellmunt, and G. Sonpavde et al. ICUD-EAU International Consultation on Bladder Cancer 2012: chemotherapy for urothelial carcinoma - neoadjuvant and adjuvant settings Eur Urol 63 2013 58 66
24. A. Stenzl, N.C. Cowan, and M. De Santis et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines [in Spanish] Actas Urol Esp 36 2012 449 460
25. A.M. D'Souza, K.S. Pohar, T. Arif, S. Geyer, and D.L. Zynger Retrospective analysis of survival in muscle-invasive bladder cancer: impact of pT classification, node status, lymphovascular invasion, and neoadjuvant chemotherapy Virchows Arch 461 2012 467 474
26. J.A. Nieuwenhuijzen, A. Bex, and W. Meinhardt et al. Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer J Urol 174 2005 80 85
27. W. Kassouf, P.K. Agarwal, and H.B. Grossman et al. Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy Urology 73 2009 147 152
28. N. Houssami, P. Macaskill, G. von Minckwitz, M.L. Marinovich, and E. Mamounas Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy Eur J Cancer 48 2012 3342 3354
29. M. Maas, P.J. Nelemans, and V. Valentini et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data Lancet Oncol 11 2010 835 844
30. B.E. Yuh, N. Ruel, T.G. Wilson, N. Vogelzang, and S.K. Pal Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer J Urol 189 2013 1682 1686
31. J. Bellmunt, H. von der Maase, and G.M. Mead et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987 J Clin Oncol 30 2012 1107 1113
32. W.M. Stadler, S.P. Lerner, and S. Groshen et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status J Clin Oncol 29 2011 3443 3449
33. C.J. Weight, J.A. Garcia, and D.E. Hansel et al. Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series Cancer 115 2009 792 799
34. T.A. Splinter, H.I. Scher, and L. Denis et al. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer - Genitourinary Group J Urol 147 1992 606 608
35. D.E. Hansel, M.B. Amin, and E. Comperat et al. A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens Eur Urol 63 2013 321 332
36. H.W. Herr, J.R. Faulkner, H.B. Grossman, and E.D. Crawford Pathologic evaluation of radical cystectomy specimens: a cooperative group report Cancer 100 2004 2470 2475
37. College of American Pathologists Guidelines for data to be included in consultation reports on breast cancer, bladder cancer, and Hodgkin's disease Pathologist 40 1986 18 23